The tyranny of non-inferiority trials

Opportunities to decrease the toxicity and cost of approved treatment regimens with lower dose, less frequent, or shorter duration alternative regimens have been limited by the perception that alternatives must be non-inferior to approved regimens. Non-inferiority trials are large and expensive to d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology Jg. 25; H. 10; S. e520 - e525
Hauptverfasser:	Tannock, Ian F, Buyse, Marc, De Backer, Mickael, Earl, Helena, Goldstein, Daniel A, Ratain, Mark J, Saltz, Leonard B, Sonke, Gabe S, Strohbehn, Garth W
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Elsevier Ltd 01.10.2024 Elsevier Limited
Schlagworte:	Adjuvants Cancer therapies Chemotherapy Clinical trials Clinical Trials as Topic Cost-Benefit Analysis Drug dosages Equivalence Trials as Topic FDA approval Hematology, Oncology, and Palliative Medicine Humans Meta-analysis Neoplasms - drug therapy Patient-centered care Pharmaceutical industry Research Design Schedules Toxicity United States > US
ISSN:	1470-2045, 1474-5488, 1474-5488
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!